+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Vaxart Inc (VXRT) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 49 Pages
  • April 2026
  • GlobalData
  • Vaxart Inc
  • ID: 4432328
Vaxart Inc (VXRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Vaxart Inc (Vaxart) is a clinical-stage biotechnology company which focuses on developing oral recombinant vaccines. It is focused on the development of oral recombinant vaccines using its proprietary Vector-Adjuvant-Antigen Standardized Technology (VAAST) platform. The company's main activities involve the research and development of vaccine candidates targeting a range of infectious diseases, including norovirus infection, seasonal influenza, respiratory syncytial virus (RSV) infection, and coronavirus (COVID-19) disease. Additionally, Vaxart is developing a therapeutic immune-oncology vaccine targeting cervical cancer and dysplasia caused by human papillomavirus (HPV). The company's oral tablet vaccine candidates are designed to generate broad and durable immune responses, including systemic, mucosal, and T cell responses, which may enhance protection against infectious diseases and have potential clinical benefits for certain cancers and chronic viral infections. Vaxart is headquartered in San Francisco, California, the US.

Vaxart Inc Key Recent Developments

  • Mar 03, 2026: Vaxart to Host Upcoming Conference Calls
  • Feb 18, 2026: Vaxart to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
  • Jan 08, 2026: Vaxart to Participate in Global BioInnovation Forum
  • Nov 13, 2025: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Vaxart Inc - Key Facts
  • Vaxart Inc - Key Employees
  • Vaxart Inc - Key Employee Biographies
  • Vaxart Inc - Major Products and Services
  • Vaxart Inc - History
  • Vaxart Inc - Company Statement
  • Vaxart Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Vaxart Inc - Business Description
  • R&D Overview
  • Vaxart Inc - Corporate Strategy
  • Vaxart Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Vaxart Inc - Strengths
  • Vaxart Inc - Weaknesses
  • Vaxart Inc - Opportunities
  • Vaxart Inc - Threats
  • Vaxart Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Vaxart Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Mar 03, 2026: Vaxart to Host Upcoming Conference Calls
  • Feb 18, 2026: Vaxart to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
  • Jan 08, 2026: Vaxart to Participate in Global BioInnovation Forum
  • Nov 13, 2025: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results
  • Nov 05, 2025: Dynavax Enters Exclusive License Agreement for Vaxart's Oral COVID-19 Vaccine Program
  • Oct 20, 2025: Vaxart To Present Research On Second-Generation Norovirus Oral Pill Vaccine Candidate At IDWeek 2025
  • Oct 08, 2025: Vaxart to Present Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025
  • Sep 17, 2025: Vaxart Appoints W. Mark Watson as Lead Independent Director
  • Sep 10, 2025: Vaxart Reports Phase 1 Data on Second-Generation Norovirus Oral Pill Vaccine
  • Sep 02, 2025: Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D. from the Board of Directors
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Vaxart Inc, Key Facts
  • Vaxart Inc, Key Employees
  • Vaxart Inc, Key Employee Biographies
  • Vaxart Inc, Major Products and Services
  • Vaxart Inc, History
  • Vaxart Inc, Subsidiaries
  • Vaxart Inc, Key Competitors
  • Vaxart Inc, Ratios based on current share price
  • Vaxart Inc, Annual Ratios
  • Vaxart Inc, Interim Ratios
  • Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Vaxart Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Vaxart Inc, Performance Chart (2021 - 2025)
  • Vaxart Inc, Ratio Charts
  • Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Vaxart Inc, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Sinovac Biotech Ltd
  • Selva Therapeutics Inc
  • Sanofi
  • Pfizer Inc
  • Novavax Inc
  • Novartis AG
  • Moderna Inc
  • Merck & Co Inc
  • Johnson & Johnson Innovative Medicine
  • Inovio Pharmaceuticals Inc
  • HilleVax Inc
  • GSK plc
  • Genexine Inc
  • F. Hoffmann-La Roche Ltd
  • Emergent BioSolutions Inc
  • CSL Ltd
  • Ayala Pharmaceuticals Inc.
  • Anhui Zhifei Long Kema Biological Pharmaceutical Co Ltd